24150-24-1|EM-1421, often called terameprocol, is the property of the pharmaceutical company Erimos. It inhibits CDK1 . EM-1421 seems to be still in phase I/II clinical trials for the treatment of patients with refractory solid tumors . A phase I study is also conducted in order to determine the safety maximum tolerated dose, dose limiting toxicity, pharmacokinetics (clearance from the blood) of EM-1421 given to patients with leukemia, as intravenous infusion three times a week
